The lack of access to care and treatment in developing countries is an urgent and important public health challenge, as the cost of treatment products is prohibitively expensive for the majority of those affected with a bleeding disorder.
It is imperative that governments recognize that providing treatment products will ensure continued improvements in health outcomes and provide this population with sustained improvements in quality of life. In addition, governments need to continue to support and fund the healthcare infrastructure needed to support patient care. Increased government investment allows the support network for the patient to be improved, and provides a solid foundation to increase advocacy efforts.
The level of care that is currently available in Yerevan, Armenia, simply did not exist before the advent of the current model of collaboration by the patient organization, healthcare providers, government leadership, and the expansion of the World Federation of Hemophilia (WFH) Humanitarian Aid Program.
The spirit of collaboration in Armenia has resulted in a vastly improved quality of life for patients, increased access to treatment products, and the establishment of an excellent team of healthcare providers within in a state-of-the-art hemophilia treatment centre.
The remarkable level of care provided at the centre is a result of the vision, hard work, and commitment of many people, and is supported by both the Armenian Ministry of Health and the WFH Humanitarian Aid Program.
Armenia is an excellent example of the power of collaboration. This model demonstrates why it is imperative that governments around the world provide treatment products and strengthen hemophilia care in order to ensure continued improvements in health outcomes and quality of life for people with bleeding disorders.
Until countries are able to sustain a level of provision of treatment products to their bleeding disorders community, the WFH Humanitarian Aid Program will provide treatment to underserved populations that would not necessarily be able to receive life- and limb-saving interventions.
The results from the expansion of the WFH Humanitarian Aid Program demonstrate the direct impact of providing treatment for patients. An increasing number of contributors within the global bleeding disorders community have accepted the challenge of providing a sustainable and predictable supply of donated products. The visionary contribution from Bioverativ and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015 to 2020). Bioverativ and Sobi also make ongoing substantial financial contributions to support the logistics of product delivery and training of providers and patients in humanitarian aid countries. Furthermore, the eight-year commitment (2014 to 2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009 to 2018) from CSL Behring for a total of 22 million IUs, and the three-year agreement (2017 to 2019) with Green Cross for 6 million IUs, all allow for a more predictable and sustainable flow of humanitarian aid donations to the global community.
To hear personal stories about the power of collaboration to ensure government support, visit www.treatmentforall.org.